Shopping Cart 0
Cart Subtotal
USD 0

Diarrhea - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Diarrhea-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea-Pipeline Review, H2 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 8, 6, 1, 17 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diarrhea-Overview 6

Diarrhea-Therapeutics Development 7

Diarrhea-Therapeutics Assessment 16

Diarrhea-Companies Involved in Therapeutics Development 25

Diarrhea-Drug Profiles 39

Diarrhea-Dormant Projects 132

Diarrhea-Discontinued Products 135

Diarrhea-Product Development Milestones 136

Appendix 146


List Of Figure

List of Figures

Number of Products under Development for Diarrhea, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Diarrhea, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diarrhea-Pipeline by Aegis Therapeutics LLC, H2 2018

Diarrhea-Pipeline by Akthelia Pharmaceuticals Ltd, H2 2018

Diarrhea-Pipeline by Albireo Pharma Inc, H2 2018

Diarrhea-Pipeline by Allergan Plc, H2 2018

Diarrhea-Pipeline by Ardelyx Inc, H2 2018

Diarrhea-Pipeline by AzurRx BioPharma Inc, H2 2018

Diarrhea-Pipeline by Bharat Biotech Ltd, H2 2018

Diarrhea-Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018

Diarrhea-Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Diarrhea-Pipeline by DiscoveryBiomed Inc, H2 2018

Diarrhea-Pipeline by Ferring International Center SA, H2 2018

Diarrhea-Pipeline by GP Pharm SA, H2 2018

Diarrhea-Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018

Diarrhea-Pipeline by Metacrine Inc, H2 2018

Diarrhea-Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2018

Diarrhea-Pipeline by Napo Pharmaceuticals Inc, H2 2018

Diarrhea-Pipeline by Nippon Shinyaku Co Ltd, H2 2018

Diarrhea-Pipeline by Novartis AG, H2 2018

Diarrhea-Pipeline by Pfizer Inc, H2 2018

Diarrhea-Pipeline by Prokarium Ltd, H2 2018

Diarrhea-Pipeline by Protagonist Therapeutics Inc, H2 2018

Diarrhea-Pipeline by RaQualia Pharma Inc, H2 2018

Diarrhea-Pipeline by RedHill Biopharma Ltd, H2 2018

Diarrhea-Pipeline by RxBio Inc, H2 2018

Diarrhea-Pipeline by Scandinavian Biopharma Holding AB, H2 2018

Diarrhea-Pipeline by Sublimity Therapeutics Ltd, H2 2018

Diarrhea-Pipeline by Summit Therapeutics Plc, H2 2018

Diarrhea-Pipeline by Synthetic Biologics Inc, H2 2018

Diarrhea-Pipeline by Syntiron LLC, H2 2018

Diarrhea-Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Diarrhea-Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2018

Diarrhea-Pipeline by Zealand Pharma AS, H2 2018

Diarrhea-Dormant Projects, H2 2018

Diarrhea-Dormant Projects, H2 2018 (Contd..1), H2 2018

Diarrhea-Dormant Projects, H2 2018 (Contd..2), H2 2018

Diarrhea-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Diarrhea Therapeutic Products under Development, Key Players in Diarrhea Therapeutics, Diarrhea Pipeline Overview, Diarrhea Pipeline, Diarrhea Pipeline Assessment


Companies

Aegis Therapeutics LLC

Akthelia Pharmaceuticals Ltd

Albireo Pharma Inc

Allergan Plc

Ardelyx Inc

AzurRx BioPharma Inc

Bharat Biotech Ltd

Chongqing Zhifei Biological Products Co Ltd

Cosmo Pharmaceuticals NV

DiscoveryBiomed Inc

Ferring International Center SA

GP Pharm SA

Kuhnil Pharmaceutical Co Ltd

Metacrine Inc

Miyarisan Pharmaceutical Company Ltd

Napo Pharmaceuticals Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Prokarium Ltd

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

RxBio Inc

Scandinavian Biopharma Holding AB

Sublimity Therapeutics Ltd

Summit Therapeutics Plc

Synthetic Biologics Inc

Syntiron LLC

Tasly Pharmaceutical Group Co Ltd

Wuhan Institute of Biological Products Co Ltd

Zealand Pharma AS

Diarrhea-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea-Pipeline Review, H2 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 8, 6, 1, 17 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diarrhea-Overview 6

Diarrhea-Therapeutics Development 7

Diarrhea-Therapeutics Assessment 16

Diarrhea-Companies Involved in Therapeutics Development 25

Diarrhea-Drug Profiles 39

Diarrhea-Dormant Projects 132

Diarrhea-Discontinued Products 135

Diarrhea-Product Development Milestones 136

Appendix 146


List Of Figure

List of Figures

Number of Products under Development for Diarrhea, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Diarrhea, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diarrhea-Pipeline by Aegis Therapeutics LLC, H2 2018

Diarrhea-Pipeline by Akthelia Pharmaceuticals Ltd, H2 2018

Diarrhea-Pipeline by Albireo Pharma Inc, H2 2018

Diarrhea-Pipeline by Allergan Plc, H2 2018

Diarrhea-Pipeline by Ardelyx Inc, H2 2018

Diarrhea-Pipeline by AzurRx BioPharma Inc, H2 2018

Diarrhea-Pipeline by Bharat Biotech Ltd, H2 2018

Diarrhea-Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018

Diarrhea-Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Diarrhea-Pipeline by DiscoveryBiomed Inc, H2 2018

Diarrhea-Pipeline by Ferring International Center SA, H2 2018

Diarrhea-Pipeline by GP Pharm SA, H2 2018

Diarrhea-Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018

Diarrhea-Pipeline by Metacrine Inc, H2 2018

Diarrhea-Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2018

Diarrhea-Pipeline by Napo Pharmaceuticals Inc, H2 2018

Diarrhea-Pipeline by Nippon Shinyaku Co Ltd, H2 2018

Diarrhea-Pipeline by Novartis AG, H2 2018

Diarrhea-Pipeline by Pfizer Inc, H2 2018

Diarrhea-Pipeline by Prokarium Ltd, H2 2018

Diarrhea-Pipeline by Protagonist Therapeutics Inc, H2 2018

Diarrhea-Pipeline by RaQualia Pharma Inc, H2 2018

Diarrhea-Pipeline by RedHill Biopharma Ltd, H2 2018

Diarrhea-Pipeline by RxBio Inc, H2 2018

Diarrhea-Pipeline by Scandinavian Biopharma Holding AB, H2 2018

Diarrhea-Pipeline by Sublimity Therapeutics Ltd, H2 2018

Diarrhea-Pipeline by Summit Therapeutics Plc, H2 2018

Diarrhea-Pipeline by Synthetic Biologics Inc, H2 2018

Diarrhea-Pipeline by Syntiron LLC, H2 2018

Diarrhea-Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Diarrhea-Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2018

Diarrhea-Pipeline by Zealand Pharma AS, H2 2018

Diarrhea-Dormant Projects, H2 2018

Diarrhea-Dormant Projects, H2 2018 (Contd..1), H2 2018

Diarrhea-Dormant Projects, H2 2018 (Contd..2), H2 2018

Diarrhea-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Diarrhea Therapeutic Products under Development, Key Players in Diarrhea Therapeutics, Diarrhea Pipeline Overview, Diarrhea Pipeline, Diarrhea Pipeline Assessment


Companies

Aegis Therapeutics LLC

Akthelia Pharmaceuticals Ltd

Albireo Pharma Inc

Allergan Plc

Ardelyx Inc

AzurRx BioPharma Inc

Bharat Biotech Ltd

Chongqing Zhifei Biological Products Co Ltd

Cosmo Pharmaceuticals NV

DiscoveryBiomed Inc

Ferring International Center SA

GP Pharm SA

Kuhnil Pharmaceutical Co Ltd

Metacrine Inc

Miyarisan Pharmaceutical Company Ltd

Napo Pharmaceuticals Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Prokarium Ltd

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

RxBio Inc

Scandinavian Biopharma Holding AB

Sublimity Therapeutics Ltd

Summit Therapeutics Plc

Synthetic Biologics Inc

Syntiron LLC

Tasly Pharmaceutical Group Co Ltd

Wuhan Institute of Biological Products Co Ltd

Zealand Pharma AS